Vaccine Effectiveness Studies in the Field | NEJM
BEIJING (The Straits Times/ANN): China's drug regulator is set to give the green light for the first foreign-made mRNA vaccine.
Shanghai-based Fosun Pharma said the National Medical Products Administration (NMPA) recently completed an expert panel review of an mRNA Covid-19 vaccine co-developed between the company and German firm BioNTech.
Named BNT162b2, the vaccine is internationally known as the Pfizer-BioNTech vaccine, or by its brand name, Comirnaty, which is being administered in many countries around the world, including Singapore. In China, it is referred to as the Fosun-BioNTech vaccine.
Last week, Fosun said BNT162b2 was now undergoing an administrative review, and company chairman Wu Yifang told a shareholders meeting that the drugmaker was targeting to start domestic trial production by the end of August.
Caixin news magazine, citing sources close to the NMPA, said regulators were looking at administering BNT162b2 to those who have been fully vaccinated as a booster. It is unclear who will be given priority for the booster shots.
Most of the Chinese-developed vaccines, which are on an inactivated virus, have lower published efficacy rates than the others …
More on: www.thestar.com.my